Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Nanobiotix SA News

    5,495 € +1,10% +0,06 €
    10:43:33 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1J7EB
    ISIN: FR0011341205
    US-Symbol: NNBXF
    Typ: Aktie

    Ad-hocs

    04.12.23 - GlobeNewswire
    Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
    Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent ...
    07.11.23 - GlobeNewswire
    NANOBIOTIX Announces Closing of Global Offering
    PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    06.11.23 - GlobeNewswire
    NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
    PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    01.11.23 - GlobeNewswire
    NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
    PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    23.10.17 - GlobeNewswire
    NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
    NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue ...
    28.04.17 - GlobeNewswire
    NANOBIOTIX : 2016 Annual Results
    NANOBIOTIX : 2016 Annual Results Nanobiotix: 2016 Annual Results Paris, France and Cambridge, Massachusetts, USA, April 28, 2017 - NANOBIOTIX (Euronext: NANO - ISIN ...
    20.10.16 - GlobeNewswire
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia Nanobiotix's partner, PharmaEngine, has launched a new ...
    20.10.16 - GlobeNewswire
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia Nanobiotix's partner, PharmaEngine, has launched a new ...
    20.10.16 - GlobeNewswire
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
    Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia Nanobiotix's partner, PharmaEngine, has launched a new ...
    31.05.16 - GlobeNewswire
    Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology
    Nanobiotix establishes promising preclinical proof-​of-concept in Immuno Oncology Small but heading for the big time Nanobiotix establishes promising preclinical proof-of-...
    13.11.15 - GlobeNewswire
    Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened
    Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened Small but heading for the big time Nanobiotix's Soft ...

    Newssuche

    Videos

    newspaper
    08:40 Uhr +19,34%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »